|Ductal pancreatic cancer modeling and drug screening using human pluripotent stem cell–and patient-derived tumor organoids|
L Huang, A Holtzinger, I Jagan, M BeGora, I Lohse, N Ngai, C Nostro, ...
Nature medicine 21 (11), 1364-1371, 2015
|Nonsmall cell lung carcinoma with neuroendocrine differentiation—an entity of no clinical or prognostic significance|
DN Ionescu, D Treaba, CB Gilks, S Leung, D Renouf, J Laskin, ...
The American journal of surgical pathology 31 (1), 26-32, 2007
|Ocular toxicity of targeted therapies|
DJ Renouf, JP Velazquez-Martin, R Simpson, LL Siu, PL Bedard
Journal of clinical oncology 30 (26), 3277-3286, 2012
|Adjuvant chemotherapy use and outcomes of patients with high‐risk versus low‐risk stage II colon cancer|
A Kumar, HF Kennecke, DJ Renouf, HJ Lim, S Gill, R Woods, C Speers, ...
Cancer 121 (4), 527-534, 2015
|Lessons learned from the application of whole-genome analysis to the treatment of patients with advanced cancers|
J Laskin, S Jones, S Aparicio, S Chia, C Ch'ng, R Deyell, P Eirew, A Fok, ...
Molecular Case Studies 1 (1), a000570, 2015
|Homologous recombination deficiency and platinum-based therapy outcomes in advanced breast cancer|
EY Zhao, Y Shen, E Pleasance, K Kasaian, S Leelakumari, M Jones, ...
Clinical Cancer Research 23 (24), 7521-7530, 2017
|Tumor budding is an independent adverse prognostic factor in pancreatic ductal adenocarcinoma|
K O’Connor, HH Li-Chang, SE Kalloger, RD Peixoto, DL Webber, ...
The American Journal of Surgical Pathology 39 (4), 472-478, 2015
|Durvalumab with or without tremelimumab for patients with metastatic pancreatic ductal adenocarcinoma: a phase 2 randomized clinical trial|
EM O’Reilly, DY Oh, N Dhani, DJ Renouf, MA Lee, W Sun, G Fisher, ...
JAMA oncology 5 (10), 1431-1438, 2019
|Successful targeting of the NRG1 pathway indicates novel treatment strategy for metastatic cancer|
MR Jones, H Lim, Y Shen, E Pleasance, C Ch'ng, C Reisle, ...
Annals of Oncology 28 (12), 3092-3097, 2017
|Eligibility of metastatic pancreatic cancer patients for first-line palliative intent nab-paclitaxel plus gemcitabine versus FOLFIRINOX|
RD Peixoto, M Ho, DJ Renouf, HJ Lim, S Gill, JY Ruan, WY Cheung
American journal of clinical oncology 40 (5), 507-511, 2017
|A phase I/II study of the Src inhibitor saracatinib (AZD0530) in combination with gemcitabine in advanced pancreatic cancer|
DJ Renouf, MJ Moore, D Hedley, S Gill, D Jonker, E Chen, D Walde, ...
Investigational new drugs 30 (2), 779-786, 2012
|Evolution of systemic therapy for advanced pancreatic cancer|
D Renouf, M Moore
Expert review of anticancer therapy 10 (4), 529-540, 2010
|Prognostic factors and sites of metastasis in unresectable locally advanced pancreatic cancer|
RDA Peixoto, C Speers, CE McGahan, DJ Renouf, DF Schaeffer, ...
Cancer medicine 4 (8), 1171-1177, 2015
|Transcription phenotypes of pancreatic cancer are driven by genomic events during tumor evolution|
M Chan-Seng-Yue, JC Kim, GW Wilson, K Ng, EF Figueroa, GM O’Kane, ...
Nature Genetics 52 (2), 231-240, 2020
|Association between palliative resection of the primary tumor and overall survival in a population-based cohort of metastatic colorectal cancer patients|
G Gresham, DJ Renouf, M Chan, HF Kennecke, HJ Lim, C Brown, ...
Annals of surgical oncology 21 (12), 3917-3923, 2014
|Mismatch repair status may predict response to adjuvant chemotherapy in resectable pancreatic ductal adenocarcinoma|
M Riazy, SE Kalloger, BS Sheffield, RD Peixoto, HH Li-Chang, ...
Modern Pathology 28 (10), 1383-1389, 2015
|Survival for metastatic colorectal cancer in the bevacizumab era: a population-based analysis|
DJ Renouf, HJ Lim, C Speers, D Villa, S Gill, CD Blanke, SE O'Reilly, ...
Clinical colorectal cancer 10 (2), 97-101, 2011
|Regulation of pH by carbonic anhydrase 9 mediates survival of pancreatic cancer cells with activated KRAS in response to hypoxia|
PC McDonald, SC Chafe, WS Brown, S Saberi, M Swayampakula, ...
Gastroenterology 157 (3), 823-837, 2019
|The cost and cost trajectory of whole‐genome analysis guiding treatment of patients with advanced cancers|
D Weymann, J Laskin, R Roscoe, KA Schrader, S Chia, S Yip, ...
Molecular genetics & genomic medicine 5 (3), 251-260, 2017
|BCL-2 expression is prognostic for improved survival in non-small cell lung cancer|
DJ Renouf, R Wood-Baker, DN Ionescu, S Leung, H Masoudi, CB Gilks, ...
Journal of Thoracic Oncology 4 (4), 486-491, 2009